Chimerix Inc. and Omthera Pharmaceuticals Inc. – one with an antiviral based on lipid delivery, the other with a lipid-lowering therapy – established terms for their initial public offerings (IPOs), raising investor hopes for a debut like that experienced last month by Enanta Pharmaceuticals Inc., but whether the fabled "window" will open for biotech firms this year remains in question.